利用结核分枝杆菌抗原特异性γ-IFN体外释放测定评估抗结核治疗疗效的临床应用价值

探讨利用结核分枝杆菌抗原特异性γ-IFN体外释放测定评估抗结核治疗疗效的临床应用价值。研究了66例培养阳性肺结核病人抗结核治疗过程中抗原特异性γ-IFN体外释放测定结果的变化,并与结核菌素皮试结果的变化相比较。结果,抗原特异性γ-IFN体外释放测定于抗结核治疗前期(满2个月)的阳性率显著高于后期(疗程满6个月)55/66(83.3%)vs12/66(18.2%);P≤0.01],而PPD结素皮试于抗结核治疗前期及后期的阳性率分别为50/66(75.8%)vs38/66(57.6%);P>0.05]。结论:结核分枝杆菌抗原特异性γ-IFN体外释放测定评估抗结核治疗疗效较PPD结素皮试临床应用价值更大。

Practical Clinical Value of Using M. tuberculosis Antigen - Specific INF -Y Release Assay in Evaluating Anti- TB Therapeutic Result

Practical clinical value of using M.tuberculosis antigen-specific INF-Y release assay(IGRA) in evaluating anti-TB therapeutic result was studied.The change of IGRA responses during anti-TB treatment of 66 patients with culture positive pulmonary tuberculosis was investigated,and compared with PPD tuberculin skin testing(TST).Significantly more patients in the early(≤2months of anti-TB treatment)rather than the late phase(>6months)had positive IGRA responses55/66(83.3%)vs12/66(18.2%);P≤0.01],comparing the patients of positive PPD results in the early(≤2months of anti-TB treatment) and the late phase(>6months) 50/66(75.8%)vs38/66(57.6%);P>0.05].Conclusion is that the antigen-specific INF-Y release assay has higher practical clinical value than PPD tuberculin skin testing(TST) in evaluating anti-TB therapeutic result.